S&P 500   3,319.47 (-1.12%)
DOW   27,657.42 (-0.88%)
QQQ   266.87 (-1.28%)
AAPL   106.84 (-3.17%)
MSFT   200.39 (-1.24%)
FB   252.53 (-0.90%)
GOOGL   1,451.09 (-2.42%)
AMZN   2,954.91 (-1.79%)
NVDA   487.57 (-2.20%)
TSLA   442.15 (+4.42%)
BABA   272.41 (-1.20%)
CGC   16.36 (-0.24%)
GE   6.88 (-2.41%)
MU   50.74 (-0.47%)
AMD   74.93 (-2.12%)
T   28.93 (-0.48%)
F   7.23 (-0.69%)
ACB   6.53 (-5.22%)
GILD   65.05 (+0.02%)
NFLX   469.96 (-0.05%)
DIS   128.63 (-1.22%)
BAC   25.21 (-0.55%)
BA   161.14 (-3.81%)
S&P 500   3,319.47 (-1.12%)
DOW   27,657.42 (-0.88%)
QQQ   266.87 (-1.28%)
AAPL   106.84 (-3.17%)
MSFT   200.39 (-1.24%)
FB   252.53 (-0.90%)
GOOGL   1,451.09 (-2.42%)
AMZN   2,954.91 (-1.79%)
NVDA   487.57 (-2.20%)
TSLA   442.15 (+4.42%)
BABA   272.41 (-1.20%)
CGC   16.36 (-0.24%)
GE   6.88 (-2.41%)
MU   50.74 (-0.47%)
AMD   74.93 (-2.12%)
T   28.93 (-0.48%)
F   7.23 (-0.69%)
ACB   6.53 (-5.22%)
GILD   65.05 (+0.02%)
NFLX   469.96 (-0.05%)
DIS   128.63 (-1.22%)
BAC   25.21 (-0.55%)
BA   161.14 (-3.81%)
S&P 500   3,319.47 (-1.12%)
DOW   27,657.42 (-0.88%)
QQQ   266.87 (-1.28%)
AAPL   106.84 (-3.17%)
MSFT   200.39 (-1.24%)
FB   252.53 (-0.90%)
GOOGL   1,451.09 (-2.42%)
AMZN   2,954.91 (-1.79%)
NVDA   487.57 (-2.20%)
TSLA   442.15 (+4.42%)
BABA   272.41 (-1.20%)
CGC   16.36 (-0.24%)
GE   6.88 (-2.41%)
MU   50.74 (-0.47%)
AMD   74.93 (-2.12%)
T   28.93 (-0.48%)
F   7.23 (-0.69%)
ACB   6.53 (-5.22%)
GILD   65.05 (+0.02%)
NFLX   469.96 (-0.05%)
DIS   128.63 (-1.22%)
BAC   25.21 (-0.55%)
BA   161.14 (-3.81%)
S&P 500   3,319.47 (-1.12%)
DOW   27,657.42 (-0.88%)
QQQ   266.87 (-1.28%)
AAPL   106.84 (-3.17%)
MSFT   200.39 (-1.24%)
FB   252.53 (-0.90%)
GOOGL   1,451.09 (-2.42%)
AMZN   2,954.91 (-1.79%)
NVDA   487.57 (-2.20%)
TSLA   442.15 (+4.42%)
BABA   272.41 (-1.20%)
CGC   16.36 (-0.24%)
GE   6.88 (-2.41%)
MU   50.74 (-0.47%)
AMD   74.93 (-2.12%)
T   28.93 (-0.48%)
F   7.23 (-0.69%)
ACB   6.53 (-5.22%)
GILD   65.05 (+0.02%)
NFLX   469.96 (-0.05%)
DIS   128.63 (-1.22%)
BAC   25.21 (-0.55%)
BA   161.14 (-3.81%)
Log in

20 "Past Their Prime" Stocks to Dump From Your Portfolio in 2020

Posted on Friday, September 18th, 2020 by MarketBeat Staff
Did you know the S&P 500 as we know it today does not look anything close to what it looked like 30 years ago? In 1987, IBM, Exxon, GE, Shell, AT&T, Merck, Du Pont, Philip Morris, Ford and GM had the largest market caps on the S&P 500. ExxonMobil is the only company on that list to remain in the top 10 in 2017. Even just 15 years ago, companies like Radio Shack, AOL, Yahoo and Blockbuster were an important part of the S&P 500. Now, these companies no longer exist as public companies.

As the years go by, some companies lose their luster and others rise to the top of the markets. We've already seen this in the last few decades with tech companies surpassing industrial and energy companies that once dominated the S&P 500. It's hard to know what the next mega trend will be that will knock Apple, Google and Amazon off the top rankings of the S&P 500, but we do know that companies won't stay on the S&P 500 forever.

We've identified 20 companies that are past their prime. They aren't at risk of a near-term delisting from the S&P 500, but they are showing negative earnings growth for the next several years. If you own any of these stocks, consider selling them now before they become the next Yahoo, Radio Shack, Blockbuster, AOL and are sold off for a fraction of their former value.

#1 - Datadog (NASDAQ:DDOG)

Trailing Twelve Months EPS: ($0.15)
2020 EPS Estimate: $0.01
2021 EPS Estimate: ($0.04)

Stock Price: $85.69
Consensus Rating: Buy
Ratings Breakdown: 10 Buy Ratings, 8 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $87.93 (2.6% Upside)

Datadog logoDatadog, Inc provides monitoring and analytics platform for developers, information technology operations teams, and business users in the cloud in North America and internationally. Its SaaS platform integrates and automates infrastructure monitoring, application performance monitoring, and log management to provide real-time observability of customers technology stack. Read More 


#2 - Passage Bio (NYSE:GFL)

2020 EPS Estimate: ($0.04)
2021 EPS Estimate: ($0.17)

Stock Price: $22.43
Dividend Yield: 0.18 %
Consensus Rating: Buy
Ratings Breakdown: 10 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $24.86 (10.8% Upside)

Passage Bio logoGFL Environmental Inc operates as a diversified environmental services company in North America. The company offers non-hazardous solid waste management, infrastructure and soil remediation, and liquid waste management services. Its solid waste management business line includes the collection, transportation, transfer, recycling, and disposal of non-hazardous solid waste for municipal, residential, and commercial and industrial customers. Read More 

#3 - Aphria (NYSE:APHA)

Trailing Twelve Months EPS: ($0.11)
2020 EPS Estimate: ($0.03)
2021 EPS Estimate: ($0.06)

Stock Price: $4.68
P/E Ratio: 52.0
Consensus Rating: Buy
Ratings Breakdown: 8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $8.83 (88.6% Upside)

Aphria logoAphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.

#4 - Inari Medical (NASDAQ:NARI)

2020 EPS Estimate: ($0.06)
2021 EPS Estimate: ($0.23)

Stock Price: $67.23
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $61.00 (-9.3% Upside)

Inari Medical logoThere is no company description available for Inari Medical Inc

#5 - Agora (NASDAQ:API)

2020 EPS Estimate: $0.04
2021 EPS Estimate: ($0.04)

Stock Price: $47.86
Consensus Rating: N/A
Ratings Breakdown: 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: N/A

Agora logoAgora, Inc provides Real-Time Engagement Platform-as-a-Service (RTE-PaaS) in the People's Republic of China, the United States, and internationally. Its RTE-PaaS offers developers with software tools to embed real-time video, voice, and messaging functionalities into their applications. The company's enterprise-grade products include Real-Time Video, Real-Time Voice, Live Interactive Video and Audio Streaming, Real-Time Messaging, Real-Time Recording, Real-Time Streaming Acceleration, and various use case products that serves as building blocks for developers to embed the respective functions in their applications. Read More 

#6 - Cronos Group (NASDAQ:CRON)

Trailing Twelve Months EPS: $0.67
2020 EPS Estimate: ($0.09)
2021 EPS Estimate: ($0.16)

Stock Price: $5.29
P/E Ratio: 11.8
Consensus Rating: Hold
Ratings Breakdown: 4 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $9.83 (85.9% Upside)

Cronos Group logoCronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations “MMPR”. The firm typically invests in companies based in Canada. Read More 

#7 - Wayfair (NYSE:W)

Trailing Twelve Months EPS: ($10.65)
2020 EPS Estimate: $0.34
2021 EPS Estimate: ($2.08)

Stock Price: $290.09
Consensus Rating: Hold
Ratings Breakdown: 16 Buy Ratings, 13 Hold Ratings, 5 Sell Ratings.
Consensus Price Target: $243.16 (-16.2% Upside)

Wayfair logoWayfair Inc engages in the e-commerce business in the United States, Europe, and internationally. It provides approximately 14 million products for the home sector under various brands. The company offers selection of furniture, décor, decorative accents, housewares, seasonal décor, and other home goods through its sites, including Wayfair, Joss & Main, AllModern, Birch Lane, and Perigold. Read More 

#8 - Ping Identity (NYSE:PING)

Trailing Twelve Months EPS: $0.37
2020 EPS Estimate: ($0.08)
2021 EPS Estimate: ($0.10)

Stock Price: $29.89
Consensus Rating: Buy
Ratings Breakdown: 16 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $31.59 (5.7% Upside)

Ping Identity logoPing Identity Holding Corp., doing business as Ping Identity Corporation, provides intelligent identity solutions in the United States and internationally. It operates an Intelligent Identity platform, which offers secure access to any service, application, or application programming interface (API) to customers, employees, partners, and the Internet of Things. Read More 

#9 - Shopify (NYSE:SHOP)

Trailing Twelve Months EPS: ($0.94)
2020 EPS Estimate: $0.16
2021 EPS Estimate: ($0.40)

Stock Price: $901.34
Consensus Rating: Hold
Ratings Breakdown: 10 Buy Ratings, 16 Hold Ratings, 2 Sell Ratings.
Consensus Price Target: $983.46 (9.1% Upside)

Shopify logoShopify Inc provides a cloud-based multi-channel commerce platform for small and medium-sized businesses in the United States, the United Kingdom, Canada, Australia, and internationally. Its platform provides merchants with a single view of business and customers in various sales channels, including Web and mobile storefronts, physical retail locations, social media storefronts, and marketplaces; and enables to manage products and inventory, process orders and payments, ship orders, build customer relationships, leverage analytics and reporting, and access financing. Read More 

#10 - National-Oilwell Varco (NYSE:NOV)

Trailing Twelve Months EPS: ($0.72)
2020 EPS Estimate: ($0.16)
2021 EPS Estimate: ($0.39)

Stock Price: $11.74
Consensus Rating: Hold
Ratings Breakdown: 10 Buy Ratings, 12 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $17.02 (45.0% Upside)

National-Oilwell Varco logoNational Oilwell Varco, Inc designs, manufactures, and sells systems, components, and products for oil and gas drilling and production worldwide. It operates in three segments: Wellbore Technologies, Completion & Production Solutions, and Rig Technologies. The Wellbore Technologies segment offers various equipment and technologies used to perform drilling operations. Read More 

#11 - Sailpoint Technologies (NYSE:SAIL)

Trailing Twelve Months EPS: $0.04
2020 EPS Estimate: ($0.10)
2021 EPS Estimate: ($0.12)

Stock Price: $37.52
P/E Ratio: 938.2
Consensus Rating: Buy
Ratings Breakdown: 10 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $34.46 (-8.1% Upside)

Sailpoint Technologies logoSailPoint Technologies Holdings, Inc designs, develops, and markets identity governance software solutions in North America, Europe, and the Asia Pacific. The company offers on-premises software and cloud-based solutions, which empower organizations to govern the digital identities of employees, contractors, business partners, and other users, as well as manage their constantly changing access rights to enterprise applications and data across hybrid IT environments. Read More 

#12 - Vasta Platform (NASDAQ:VITL)

2020 EPS Estimate: $0.07
2021 EPS Estimate: ($0.05)

Stock Price: $38.51
Consensus Rating: Hold
Ratings Breakdown: 2 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $40.00 (3.9% Upside)

Vasta Platform logoVital Farms, Inc operates as an ethical food company in the United States. It produces five pasture-raised products sourced from animals raised on small family farms, including shell eggs, butter, hard-boiled eggs, ghee, and liquid whole eggs. The company's customers include natural retailers, mainstream retailers, and foodservice partners. Read More 

#13 - Blueprint Medicines (NASDAQ:BPMC)

Trailing Twelve Months EPS: ($7.27)
2020 EPS Estimate: $0.84
2021 EPS Estimate: ($7.12)

Stock Price: $79.45
Consensus Rating: Buy
Ratings Breakdown: 11 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $98.50 (24.0% Upside)

Blueprint Medicines logoBlueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. Read More 

#14 - Crestwood Equity Partners (NYSE:CEQP)

Trailing Twelve Months EPS: $0.01
2020 EPS Estimate: ($0.11)
2021 EPS Estimate: ($0.12)

Stock Price: $13.77
Dividend Yield: 18.17 %
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $11.17 (-18.9% Upside)

Crestwood Equity Partners logoCrestwood Equity Partners LP provides infrastructure solutions to liquids-rich natural gas and crude oil shale plays in the United States. It operates through three segments: Gathering and Processing (G&P); Storage and Transportation (S&T); and Marketing, Supply and Logistics (MS&L). The G&P segment offers gathering and transportation services for natural gas, crude oil, and produced water; and processing, treating, and compression services. Read More 

#15 - USA Compression Partners (NYSE:USAC)

Trailing Twelve Months EPS: $0.03
2020 EPS Estimate: ($0.20)
2021 EPS Estimate: ($0.33)

Stock Price: $10.87
Dividend Yield: 18.87 %
Consensus Rating: Hold
Ratings Breakdown: 2 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $13.33 (22.7% Upside)

USA Compression Partners logoUSA Compression Partners, LP provides compression services under term contracts with customers in the natural gas and crude oil industries in the United States. The company engineers, designs, operates, services, and repairs its compression units; and maintains related support inventory and equipment. Read More 

#16 - Sprint (NYSE:S)

Trailing Twelve Months EPS: $0.01
2020 EPS Estimate: ($0.18)
2021 EPS Estimate: ($0.23)

Stock Price: $8.62
Consensus Rating: Hold
Ratings Breakdown: 1 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $7.88 (-8.6% Upside)

Sprint logoSprint Corporation, together with its subsidiaries, provides various wireless and wireline communications products and services to consumers, businesses, government subscribers, and resellers in the United States, Puerto Rico, and the United States Virgin Islands. It operates in two segments, Wireless and Wireline. Read More 

#17 - Blackline (NASDAQ:BL)

Trailing Twelve Months EPS: ($0.25)
2020 EPS Estimate: ($0.30)
2021 EPS Estimate: ($0.39)

Stock Price: $82.38
Consensus Rating: Buy
Ratings Breakdown: 5 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $81.78 (-0.7% Upside)

Blackline logoBlackLine, Inc provides financial accounting close solutions delivered primarily as Software as a Service in the United States and internationally. Its solutions enable its customers to address various aspects of their financial closing process, including account reconciliations, variance analysis of account balances, journal entry capabilities, and range of data matching capabilities. Read More 

#18 - Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Trailing Twelve Months EPS: $0.69
2020 EPS Estimate: ($0.48)
2021 EPS Estimate: ($0.99)

Stock Price: $43.10
Consensus Rating: Buy
Ratings Breakdown: 9 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $62.20 (44.3% Upside)

Arrowhead Pharmaceuticals logoArrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. Read More 

#19 - Uniqure (NASDAQ:QURE)

Trailing Twelve Months EPS: ($3.11)
2020 EPS Estimate: $0.41
2021 EPS Estimate: ($0.72)

Stock Price: $41.69
Consensus Rating: Buy
Ratings Breakdown: 12 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $75.69 (81.6% Upside)

Uniqure logouniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure. Read More 

#20 - Harte Hanks (NYSE:HHS)

Trailing Twelve Months EPS: ($3.20)
2020 EPS Estimate: $0.24
2021 EPS Estimate: ($0.19)

Stock Price: $4,900.00
Consensus Rating: N/A
Ratings Breakdown: 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: N/A

Harte Hanks logoHarte Hanks, Inc provides various multi-channel marketing services in the United States and internationally. The company provides agency services, such as customer engagement solutions in direct and digital communications for consumer and business-to-business markets; digital services, including search engine management, display, digital analytics, Website development and design, digital strategy, social media, email, e-commerce, and interactive relationship management services; and database marketing and business-to-business lead generation solutions that offer insight and analytics, customer data integration, and marketing communications tools. Read More 

 

6 Stocks That May Not Survive the Coronavirus

Companies that are in a shaky financial position may sometimes attract investors in a bull market. Traders seeking a short-term profit can often use an oversold condition to capture a quick gain. But in a bear market, these companies frequently are left on the sidelines.

But a declining stock price by itself should not be enough to scare investors off. What investors really need to pay attention to is the company’s ability to finance existing debt or take on additional debt. Companies with low credit ratings face the problem of having too much debt on their books and an inability to finance it at more favorable rates.

That’s one reason we’ve put together this presentation that highlights 6 companies that may not survive the coronavirus. These companies have low stock prices. In fact, many of them are, or will be, in danger of being delisted if they cannot bring their stock above the $1 threshold. And on top of that, these companies each carry credit ratings of CCC+ or lower and are at risk of seeing those ratings even go lower.

Each of the companies presented here are considered to be among the weakest, if not the weakest, in their sector. If you have any of these falling knives in your portfolio now is the time to cut your losses and walk away.

View the "6 Stocks That May Not Survive the Coronavirus" Here.






Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.